Late-breaking data demonstrate abbott's freestyle libre® 3 system is most accurate 14-day continuous glucose monitor

Data at the american diabetes association 82nd scientific sessions show abbott's freestyle libre 3 system is first and only 14-day continuous glucose monitor (cgm) system to achieve a mean absolute relative difference (mard) of less than 8% additional data show the positive impact of the freestyle libre system and libreview app in helping healthcare professionals make earlier treatment decisions and detecting hypoglycemic events abbott park, ill., june 5, 2022 /prnewswire/ -- abbott (nyse: abt) today announced late-breaking clinical data that demonstrate the freestyle libre® 3 system has an overall mean absolute relative difference (mard) of 7.9%,1 making it the first and only 14-day continuous glucose monitoring (cgm) system to achieve a sub-8% overall mard.
ABT Ratings Summary
ABT Quant Ranking